Dr. Grandori is a biotech entrepreneur and cancer molecular biologist with experience in academia and pharma. She received her MD from the University of Rome and a PhD from The Rockefeller University. Dr. Grandori completed her post-doctoral training at MIT and at the Fred Hutchinson Cancer Research Center (FHCRC). From 2009 to 2014, Dr. Grandori was the principal investigator of a laboratory at FHCRC, where she pioneered discovery and development of therapeutic targets to tackle the undruggable MYC oncogene. In 2009, Dr. Grandori was recruited to establish the Quellos High Throughput Screening Core at the University of Washington, for which she received a presidential entrepreneurial award. In 2011, Dr. Grandori founded, and continues to direct, Cure First, a not-for-profit research organization. Since 2015, Dr. Grandori has served as CEO/CSO of SEngine Precision Medicine.